[Skip to the guide](#content) 

[Portland Peptide Clinic](/) 

A Portland pre-visit checklist that fits on a pair of pages; conducts no checkups itself.

[Pre-visit checks](/) [Cost questions](/cost-brief) 

<a id="content"></a>

[Open the checklist](#before-visit) 

<a id="home-title"></a>

# A checklist to take to a Portland peptide clinic

This guide sees no one, writes no prescriptions, and makes no bookings.

<a id="before-visit"></a>

<a id="index-heading"></a>

## Keep these checks together

[The prescriber](#prescriber) [The assessment](#assessment) [The pharmacy](#pharmacy) [The follow-up](#follow-up) 

<a id="health-question"></a>

## Prepare for the first conversation

Bring the name of the proposed medicine, the prescriber’s name, and a request for the full cost. Then put your own concern into plain words: what is bothering you, what you hope to change, and what you want to ask before deciding.

Protein building blocks are called amino acids. Link a short chain of those blocks and it is a peptide. Calling a substance a peptide does not make it [an approved medicine](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) or show that it can lawfully be supplied. That distinction was checked November 3, 2026.

Keep the checks below beside you while reading a clinic’s answers. Check a box when the answer is clear to you. An unanswered item can stay open; it does not need to be guessed.

<a id="prescriber"></a>

<a id="prescriber-heading"></a>

## Check who would prescribe

Ask who will decide on treatment, and get that person’s full name. Keep that name with the details of the service you are considering.

The [Oregon Medical Board](https://www.oregon.gov/omb/Licensing/Pages/License-Verification.aspx) licenses doctors and physician associates, called PAs. A PA is a licensed health professional who is not a doctor. Nurse practitioners are licensed through the Oregon State Board of Nursing. These are nurses trained further to assess and treat illness. These board routes were checked November 3, 2026.

PAs can diagnose illness, treat it and prescribe through remote care under Oregon law checked November 3, 2026.

- [ ] Write down the prescriber’s full name and professional role.

- [ ] Use the appropriate board’s official license check.

- [ ] Ask who makes the decision if the proposed treatment is unsuitable.

Doctors and PAs treating someone in Oregon from a distance generally need an Oregon license, with narrow exceptions. Nurse practitioners need a license from [Oregon’s nursing board](https://www.oregon.gov/osbn/pages/index.aspx). Those licensing rules were checked November 3, 2026.

If the visit will happen while you are traveling, name the state where you will actually be. Ask the service to confirm the arrangement before paying.

[Open the medical board’s verification page](https://www.oregon.gov/omb/Licensing/Pages/License-Verification.aspx) 

<a id="assessment"></a>

<a id="assessment-heading"></a>

## Ask how the assessment works

Choose between a local in-person clinic and licensed telehealth by asking how the visit would address your concern. Telehealth means care delivered from a distance through electronic contact.

Your first visit with a doctor or PA can happen from home: Oregon [does not require an in-person visit](https://www.oregon.gov/omb/Topics-of-Interest/Pages/Telemedicine.aspx) just to become that person’s patient. That rule was checked November 3, 2026. The standard of care stays the same. Any needed exam, test or referral still has to be arranged.

- [ ] Ask how you can speak with your clinician, the person assessing you and deciding on treatment, and ask your own questions.

- [ ] Bring your current medicines, health history and main concerns to discuss.

- [ ] Ask what would prompt an examination, a test or a referral elsewhere.

The Oregon Medical Board’s guidance, checked November 3, 2026, rejects a questionnaire standing alone without [personal review and assessment](https://www.oregon.gov/omb/board/Philosophy/Pages/Telemedicine.aspx). Care can still involve sending answers for later review; the guidance calls for a personal assessment and a record of your health history and evaluation.

Oregon law also recognizes care where you and the doctor or PA exchange information without being online at the same time, as checked November 3, 2026.

A useful answer tells you what happens during the assessment and what happens if no prescription is offered. Ask for unfamiliar terms to be put into ordinary words.

<a id="pharmacy"></a>

<a id="pharmacy-heading"></a>

## Find out who supplies the medicine

Keep the supplying pharmacy’s name with the rest of your visit notes. Ask who prepares the medicine, who sends it, and who can answer questions about its label.

Under Oregon rules checked November 3, 2026, [a pharmacy outside the state needs Oregon registration](https://secure.sos.state.or.us/oard/viewSingleRule.action?ruleVrsnRsn=308892) as well as registration where it operates before supplying someone in Oregon. The Oregon pharmacy board’s public search covers pharmacists and pharmacy facilities. Each record notes whether the board has taken disciplinary action against that license or registration. This means a penalty or other formal action against the license or registration. Complaints are confidential.

- [ ] Get the supplying pharmacy’s full name before committing.

- [ ] Check the facility record with Oregon’s pharmacy board.

- [ ] Write down the pharmacist’s contact route for label, storage and delivery questions.

A federal rule checked November 3, 2026 says [registration alone grants no product approval](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved). The Food and Drug Administration (FDA) makes this distinction.

Read the medicine name back to the clinician. Ask which is proposed: a finished product with FDA approval, or a preparation mixed to order. Ask for the answer behind any badge on a website.

[Use Oregon’s pharmacy and facility search](https://orbop.mylicense.com/verification/) 

<a id="follow-up"></a>

<a id="follow-up-heading"></a>

## Set the follow-up plan

Ask for a contact plan while you are still comparing options. Write down whom to contact, how to reach them, and what the service says about replies between visits.

- [ ] Name the person or service handling questions after the visit.

- [ ] Find out who reviews test results and when the care plan gets another review.

- [ ] Ask what happens if you stop treatment, move or change clinicians.

After a prescription, patients need a way to reach the prescriber with questions. The Federation of State Medical Boards included this point in its [May 2026 prescribing guidance](https://www.fsmb.org/siteassets/advocacy/policies/guidance-on-recent-trends-in-prescribing-and-dispensing-adopted.pdf). Each state sets its own enforceable rules; this document advises boards.

Ask the clinician which symptoms call for a message, a prompt assessment or emergency help. Request an answer about the particular medicine being proposed, rather than a general answer about peptides.

MedlinePlus lists breathing trouble and swelling of the tongue among [signs of a severe allergic reaction](https://medlineplus.gov/ency/article/000844.htm). Its emergency advice is to call 911 for severe symptoms.

<a id="medicine-status"></a>

<a id="status-heading"></a>

## Ask what the proposed medicine actually is

Have the clinician name the exact product and explain why it is being proposed for your concern. A general claim about peptides cannot answer that question.

Tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) have [FDA-approved products](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf) as of November 3, 2026. Ozempic and Mounjaro have approvals to treat type 2 diabetes. Wegovy and Zepbound have approvals for long-term weight control. These products were reviewed by the Food and Drug Administration, or FDA.

[Compounding](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) means preparing a medicine to order instead of providing a ready-made drug-company product. A licensed pharmacist or physician can do this work, as can a registered outsourcing facility. An outsourcing facility is a site registered to prepare several supplies of sterile medicine together, called a batch. Sterile describes something with no living germs.

At the November 3, 2026 check, FDA had granted [no approval to compounded preparations](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). They are marketed without FDA first reviewing quality, the evidence on effectiveness and whether the product is safe.

FDA’s published concerns include [contamination and incorrect amounts of active ingredient](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) when compounding is done poorly. The active ingredient does the intended work of the drug.

### What the recent peptide draft means

[Section 503A](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) sets federal conditions for a pharmacist or doctor preparing a prescription medicine for an identified patient. The law’s other conditions still have to be met. A peptide draft dated October 30, 2026 came from the Department of Health and Human Services, known as HHS.

The 503A bulks list names extra raw ingredients allowed for making prescription medicines under that part of federal law.

The [draft concerns enforcement](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) when state-licensed pharmacies or physicians use semax, KPV, BPC-157, epitalon, TB-500 or MOTS-c despite the 503A restrictions on raw ingredients. HHS says it does not intend to take action under the conditions in the draft. This list concerns proposed compounding policy, not FDA-approved uses for these ingredients.

The draft’s [conditions](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) require a prescription for an individual patient and a single ingredient. Only the chemical forms and ways of taking the medicine specified in Appendix B are included. A chemical form is the exact version of the ingredient; a route is how it enters the body, such as by mouth or injection. Ask the prescriber to show how the proposed medicine meets every condition and matches Appendix B.

Blends, which combine ingredients, are [excluded from the draft](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf). The draft also excludes section 503B outsourcing facilities, which are sites registered with FDA to prepare sterile medicines in batches. These sites do not need a prescription for each named patient.

[None of these six peptides was on the 503A ingredient list](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm) in the November 3, 2026 check. The draft is nonbinding and grants no FDA approval. The draft creates no right to compound; that is what nonbinding means here.

HHS reports that the July 2026 advisory panel [recommended adding six of the seven peptides](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf) it reviewed to the 503A ingredient list. The panel’s advice did not itself change the list.

If this draft is offered as the reason for a prescription, ask the prescriber to explain the conditions for that exact preparation. Keep that answer with the product name and pharmacy details.

### Reasons to pause

For prescription drugs, dispensing [without the required prescription](https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy) breaks federal law; that rule was checked November 3, 2026. FDA’s warnings also address products labeled for research but marketed as human treatments.

If the offer skips a prescription, hides the supplying pharmacy or leaves no way to ask questions, keep those points unresolved. Ask for a direct answer before treating the offer as a care plan.

<a id="cost-next"></a>

## Take the cost questions with you

Put the visit, medicine, tests and ongoing care on the same quote before comparing options. Leave unclear charges marked as questions.

[Work through the cost questions](/cost-brief) 

<a id="page-notes"></a>

<a id="notes-heading"></a>

## Sources for these checks

Peptide terms and approved-product examples; status checked November 3, 2026.

[Read FDA’s compounding Q&A](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)  [Read the Wegovy label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf)  [Read the Mounjaro label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf)  

Official Oregon routes for checking the person who would prescribe.

[License Verification](https://www.oregon.gov/omb/Licensing/Pages/License-Verification.aspx)  [Find the nursing board’s lookup link](https://www.oregon.gov/osbn/pages/index.aspx)  

Oregon license and assessment information, checked November 3, 2026; the board’s statement describes its expectations for care and is guidance, not a separate law.

[Read the medical board’s remote-care rules](https://www.oregon.gov/omb/Topics-of-Interest/Pages/Telemedicine.aspx)  [Read the board’s approach to remote care](https://www.oregon.gov/omb/board/Philosophy/Pages/Telemedicine.aspx)  

Oregon pharmacy registration and the public facility check.

[Online License/Registration Verification](https://orbop.mylicense.com/verification/)  [Read Oregon’s rule for out-of-state pharmacies](https://secure.sos.state.or.us/oard/viewSingleRule.action?ruleVrsnRsn=308892)  

Federal compounding limits, product review and quality concerns.

[Read the federal compounding questions](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers)  [Check what FDA approval means](https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved)  

The medical-board federation’s prescribing guidance, adopted May 2026.

[Read the federation’s prescribing guidance](https://www.fsmb.org/siteassets/advocacy/policies/guidance-on-recent-trends-in-prescribing-and-dispensing-adopted.pdf)  

Emergency information about severe allergic reactions.

[Read MedlinePlus on severe allergic reactions](https://medlineplus.gov/ency/article/000844.htm)  

The October 30, 2026 HHS draft and its appendices; checked November 3, 2026.

[Read the full HHS draft and appendices](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf)  [Read the published notice of the draft](https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm)  

Prescription checks and research-label concerns.

[Check FDA’s online-pharmacy signs](https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/considering-online-pharmacy)  [Read FDA’s concerns about unapproved weight-loss drugs](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss)  

These pages are a guide for preparing questions; no clinic operates here and no medicines are sold.

[Pre-visit checks](/) [Cost questions](/cost-brief) [Text version](/index.md) 

© Portland Peptide Clinic